This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q3 Earnings Season Moving Along
by Zacks Equity Research
Q3 Earnings Season Moving Along
Reasons for Optimism: Q3 Earnings, Infrastructure
by Mark Vickery
Not only good Q3 numbers, but Covid vaccine news and hope for an infrastructure passage are keeping bullish sentiment in the market.
Pfizer's (PFE) Comirnaty Booster Dose Achieves 95.6% Efficacy
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce promising data from a late-stage study evaluating the booster dose of their COVID-19 vaccine, Comirnaty.
FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses
by Indrajit Bandyopadhyay
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.
J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
by Zacks Equity Research
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
Best Single Trading Day in Months for Dow, Nasdaq, S&P
by Mark Vickery
The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $250.33 in the latest trading session, marking a +0.37% move from the prior day.
Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BNTX) Outperforming Other Medical Stocks This Year?
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose
by Zacks Equity Research
Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.
J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab
by Zacks Equity Research
J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.
Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion
by Ekta Bagri
Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.
Market Bears Take The Bulls By The Horns As Q4 Kicks Off
by Daniel Laboe
We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows
BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study
by Zacks Equity Research
BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.
Vaccine Stocks Down Following Merck's COVID-19 Pill Success
by Kinjel Shah
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal
by Zacks Equity Research
Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $277.44, marking a +0.33% move from the previous day.
United Airlines (UAL) to Sack Workers on Vaccine Refusal Grounds
by Zacks Equity Research
The 593 workers of United Airlines (UAL) have not applied for exemption from getting jabbed on medical or religious grounds.
Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA
by Zacks Equity Research
Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.
Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies
by Zacks Equity Research
Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.
AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space
by Zacks Equity Research
AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.